Detalhe da pesquisa
1.
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Eur J Haematol
; 111(6): 863-871, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37670560
2.
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
Blood
; 135(22): 1929-1945, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187362
3.
A novel GAB2::BRAF fusion in cutaneous non-Langerhans-cell histiocytosis with systemic involvement.
J Cutan Pathol
; 49(8): 727-730, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332933
4.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Blood
; 133(17): 1876-1887, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30782611
5.
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility.
Haematologica
; 106(8): 2114-2120, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32646891
6.
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis.
J Natl Compr Canc Netw
; : 1-10, 2021 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161925
7.
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(11): 1277-1303, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34781268
8.
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.
J Natl Compr Canc Netw
; : 1-4, 2020 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32197238
9.
Aleukemic mast cell leukemia, well-differentiated and chronic type.
Ann Hematol
; 102(6): 1613-1615, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016166
10.
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.
J Natl Compr Canc Netw
; 16(11): 1289-1303, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442731
11.
Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Am J Hematol
; 93(4): 546-552, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318644
12.
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Br J Haematol
; 172(2): 238-45, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26568032
13.
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
Br J Haematol
; 170(3): 349-55, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25854284
14.
Development of a hematology/oncology ICD-10 documentation job aid.
J Natl Compr Canc Netw
; 13(4): 435-40, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25870380
15.
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
J Natl Compr Canc Netw
; 13(9): 1079-95, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26358792
16.
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol
; 90(6): 483-6, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25689471
17.
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Am J Hematol
; 90(4): 295-300, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25545153
18.
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.
Br J Haematol
; 166(3): 375-81, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24749757
19.
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Haematologica
; 99(1): 54-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24142996
20.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Haematologica
; 104(4): e143-e146, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409798